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Abstract
The abundant flavonoid aglycone, naringenin, which is responsible for the bitter taste in grapefruits, has been shown to
possess hypolipidemic and anti-inflammatory effects both in vitro and in vivo. Recently, our group demonstrated that
naringenin inhibits hepatitis C virus (HCV) production, while others demonstrated its potential in the treatment of
hyperlipidemia and diabetes. However, naringenin suffers from low oral bioavailability critically limiting its clinical potential.
In this study, we demonstrate that the solubility of naringenin is enhanced by complexation with b-cyclodextrin, an FDA
approved excipient. Hydroxypropoyl-b-cyclodextrin (HPbCD), specifically, increased the solubility of naringenin by over 400-
fold, and its transport across a Caco-2 model of the gut epithelium by 11-fold. Complexation of naringenin with HPbCD
increased its plasma concentrations when fed to rats, with AUC values increasing by 7.4-fold and Cmax increasing 14.6-fold.
Moreover, when the complex was administered just prior to a meal it decreased VLDL levels by 42% and increased the rate
of glucose clearance by 64% compared to naringenin alone. These effects correlated with increased expression of the PPAR
co-activator, PGC1a in both liver and skeletal muscle. Histology and blood chemistry analysis indicated this route of
administration was not associated with damage to the intestine, kidney, or liver. These results suggest that the
complexation of naringenin with HPbCD is a viable option for the oral delivery of naringenin as a therapeutic entity with
applications in the treatment of dyslipidemia, diabetes, and HCV infection.
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Introduction
In recent years, polyphenols, and flavonoids in particular, have
emerged as a class of natural products shown to have anti-oxidant,
anti-atherogenic, and normolipidemic effects [1]. One of the most
abundant is the citrus flavonoid-glycoside naringin, which is
responsible for the bitter taste in grapefruit. Naringin is hydrolyzed
to naringenin by gut flora prior to being absorbed [2]. Naringenin
has been widely studied, and has been reported to be an
antioxidant [3,4], MTP and ACAT inhibitor [5,6], and a
regulator of cytochrome P450 (CYP450) enzymes including,
CYP1A, CYP3A4, and CYP4A [7,8,9]. The ability of naringenin,
and its glucuronide metabolites, to reduce plasma cholesterol levels
has been demonstrated in vivo [10,11,12], while its ability to reduce
ApoB secretion has been demonstrated extensively in vitro [13,14].
A recent clinical trial in hypercholesterolemic patients demon-
strated that a 400 mg/day dose of naringin lowered LDL levels by
17% [3]. Similar cholesterol lowering effects of naringenin were
demonstrated in rabbits [11] and rats [12]. More recently, Huff
and coworkers have shown that naringenin helps correct many of
the lipid disturbances associated with diabetes in transgenic mice
lacking the LDL receptor that were fed a western-style diet,
including correction of VLDL overproduction, amelioration of
hepatic steatosis, and attenuation of dyslipidemia [10], while our
group demonstrated that naringenin blocked the assembly of
VLDL and infectious hepatitis C virus (HCV) particles in
Huh7.5.1 cells and primary human hepatocytes [15].
Importantly, our recent findings demonstrate that naringenin is
a dual-PPAR agonist, activating both PPARa and PPARc through
the induction of their co-activator PGC1a [16]. At the same time,
naringenin directly inhibits LXRa, which controls HMG-CoA
reductase (HMGR) expression in the liver [16]. These results
suggest that naringenin could potentially replace the actions of
fibrates (PPARa agonists), thiazolidenediones (PPARc agonists),
and statins (HMGR inhibitors) in the treatment of type-2 diabetes
or hyperlipidemia [16].
Regretfully, the clinical relevance of naringenin is limited by its
low solubility and minimal bioavailability owing to its largely
hydrophobic ring structure. In this study, b-cyclodextrins were
examined as potential excipients to enhance the solubility and
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enteral uptake of the flavonoid. Cyclodextrins are a family of cyclic
oligosaccharides that create a 3-dimensional toroid structure,
providing a cavity that can accommodate small hydrophobic
molecules, such as cholesterol or steroids. Cyclodextrins can
therefore be used as excipients to improve the solubility of
hydrophobic drugs with similar structure [17,18]. Specifically, the
bioavailability of rutin, a flavonoid-glycoside similar in structure to
naringin, was significantly enhanced by complexation with 2-
hydroxypropyl-b-cyclodextrin (HPbCD) [19]. Here, we demon-
strate that HPbCD enhances the solubility of naringenin, increases
its transport across a Caco-2 model of human gut epithelium, and
elevates its plasma concentrations following oral administration to
Sprague-Dawley rats. When the complex is given right before a
meal rich in glucose and fat, it decreased VLDL levels by 42% and
increased the rate of glucose clearance by 64% compared to
naringenin alone. These effects correlated with increased mRNA
expression of the PPAR co-activator, PGC1a in both liver and
skeletal muscle, strengthening recent evidence of a PPAR-mediated
mechanism of action [16]. Combined with HPbCD’s strong safety
record, our results suggest that HPbCD-naringenin complexes
could be used to efficiently deliver the flavonoid in patients for the
treatment of dyslipidemia, arthrosclerosis, and HCV infection.
Results
b-Cyclodextrins increase the solubility of naringenin
Molecules similar to naringenin in structure and size were
previously shown to be solubilized by complexation with b-
cyclodextrin. To explore if naringenin is similarly solublized we
generated complexes with b-cyclodextrin (bCD), methyl b-
cyclodextrin (mbCD), and 2-hydroxypropyl-b-cyclodextrin
(HPbCD). UV analysis indicated that complexation with cyclo-
dextrins resulted in a very small shift in naringenin’s absorption
spectrum (Figure 1A). Concentrations of naringenin were then
extrapolated from the previously obtained standard curve
(Figure 1C). As expected, naringenin solubility in water was
3661 mM, consistent with previously observed results [20]. Upon
complexation with cyclodextrins, the amount of solubilized
naringenin increased, as summarized in Table 1. The three
bCDs solubilized naringenin in decreasing order mbCD .
HPbCD . bCD resulting in a significant 526, 437, and 132-
fold, enhancement in solubility respectively (p,0.01).
HPbCD enhances the transport of naringenin across a
Caco-2 monolayer
While mbCD was the most effective in enhancing the solubility
of naringenin, its use is associated with soft tissue and kidney
damage due to its detergent-like effect on membranes [21]. On the
other hand, HPbCD does not cause hemolysis or irritation due to
its low surface tension and is generally regarded as a safe excipient
[22]. We therefore examined the ability of HPbCD to enhance the
transport of naringenin across a monolayer of Caco-2 cells, an
established model for drug transport across the human gut
epithelium.
Caco-2 cells were grown for 21 days on collagen-coated 1 cm2
porous transwell membranes (0.4 mm pores) on which cells formed
differentiated monolayers, expressing major tight junction pro-
teins, microvilli, and drug transporters (Figure 2B) [23].
Transepithelial Electrical Resistance (TEER) and Lucifer yellow
transport were used to evaluate epithelial integrity and maturity of
the monolayers. The apparent permeability coefficient, Papp,
remained between 6 and 761027 cm/sec through the course of
the experiment, demonstrating that the Caco-2 layer was intact.
11 mM naringenin, either alone or in a complex form with
45 mM HPbCD, was added to the top assay chamber. Samples
were taken from both the top, apical chamber and the bottom,
basal chamber at different time intervals and assayed for
concentrations of naringenin (Figure 2A). In the presence of
HPbCD, the concentration of naringenin at the basal chamber
was increased from 0.046 0.02 mM to 0.516 0.07 mM, repre-
senting an 11-fold enhancement of transport across the Caco-2
monolayer. The integrity of the monolayer prior to and following
the experiment was similar to control for both treatments.
HPbCD enhances the bioavailability of naringenin in rats
To test whether cyclodextrin would enhance the oral bioavail-
ability of naringenin, adult Sprague-Dawley rats were fed 20
mg/kg body weight naringenin either alone, or as a 1:16 (wt/wt)
HPbCD-naringenin complex, using an oral gavage. Blood samples
were collected sequentially for 10 hrs from the carotid artery using
the previously placed catheter into tubes containing heparin.
Immediately after collection, plasma was separated and stored at
280uC for further analysis. At the conclusion of the experiment,
all animals were sacrificed, and liver, kidney, and bowel specimens
Figure 1. Cyclodextrins enhance the solubility of naringenin. (a)
Complexation of naringenin with cyclodextrins resulted in minimal shift
in the compound UV absorption spectrum. (b) Naringenin solubility in
water was measured to be 3661 mM, whereas its soluble fraction
increased with the addition of bCD, mbCD, or HPbCD by 132-fold, 526-
fold, and 437-fold, respectively.
doi:10.1371/journal.pone.0018033.g001
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were collected for histology. In an additional experiment, animals
were placed in metabolic cages and urine was collected and
pooled. Total naringenin (flavonoid and glucuronide) was
determined by LC-MS as described above.
The complexation of HPbCD with naringenin significantly
affected the plasma concentration versus time profile of the
flavonoid (Figure 2C). Complexation with HPbCD significantly
increased the AUC0-10 of naringenin from 2.060.5 hr6mg/ml to
15.064.9 hr6mg/ml representing a 7.4-fold increase in bioavail-
ability (p = 0.005, n = 3). Naringenin’s maximal concentration,
Cmax, increased from 0.360.1 mg/ml to 4.361.2 mg/ml repre-
senting a 14.6-fold increase (p = 0.002, n= 3). The calculated half-
life for naringenin in plasma remained unchanged in both
conditions at 2.3 hours, consistent with values previously reported
in humans [24,25] and rats [26]. The percentage of free
naringenin in plasma was in both cases ,3% with the reminder
in the glucuronide form. Finally, analysis of urine samples in two
animals demonstrated unchanged renal clearance of 4.2 6 1%.
HPbCD–Naringenin complex reduces VLDL production
and enhances glucose clearance following a lipid and
glucose rich meal in rats
To assess if a single dose of HPbCD–naringenin could affect rat
metabolism we administered naringenin or its complex orally, 30
minutes before the oral administration of a meal high in lipids
(1 ml/kg) and glucose (1 g/kg). Glucose levels were measured
sequentially for 2 hrs after the meal (Figure S1). Interestingly, rats
that were administered the HPbCD–naringenin complex showed
a significantly 64% higher (p = 0.05, n= 3) rates of glucose
clearance, compared to rats given naringenin alone (Figure 3A).
Previous work showed that the maximal level of VLDL in blood is
reached 3 to 4 hrs after a meal. Here we show that 3.5 hrs after
the meal, plasma levels of ApoB100, the structural protein of
VLDL were significantly 42% lower (p = 0.05, n = 3) then rats
given naringenin alone (Figure 3C). Interestingly, triglyceride
levels in the same rats increased, but not significantly (p = 0.24,
n = 3). This response is similar to that of fibrates that, like
naringenin, act through PPARa, and are thought to occur due to a
flux of chylomicrons from the intestine.
Recently, we demonstrated that naringenin is a dual-PPAR
agonist, activating both PPARa and PPARc through the induction
of their co-activator PGC1a [16]. To examine if naringenin acts
through a similar mechanism in vivo we carried out qRT-PCR
analysis on samples of liver and skeletal muscle taken 3.5 hrs after
the meal. The expression of PGC1a significantly increased by
2306100% (p= 0.02, n= 3) and 118660% in skeletal muscle and
liver, respectively (Figure 3B).
Oral administration of HPbCD-naringenin was not
associated with adverse effects
Lastly, we wished to examine if the administration of the
HPbCD-naringenin complex was associated with tissue or organ
damage. Liver, kidneys and intestine were removed 10 hrs
following oral administration of the complex and showed no gross
pathological changes (data not shown). Histological characteriza-
tion by a blind observer demonstrated that the small intestine,
kidney, and liver sections showed no evidence of tissue injury or
inflammation in both groups. Liver sections showed no evidence of
hepatocyte damage or neutrophil infiltration to the portal area,
while kidney and intestine sections show no tubular/glomerular
damage, edema or epithelial damage, respectively (Figure 4).
One intestine section in a single rat showed a localized small
infiltrate, which did not appear to be related to the experiment.
Comprehensive metabolic analysis was carried out on serum
samples taken from rats, 10 hours after the treatment with
HPbCD-naringenin, naringenin alone, as well as rats treated with
saline as a control. The biochemical examination revealed no
major changes (Table 2). Glucose and electrolytes levels were
within normal values, as were urea and creatinine levels,
suggesting kidney function was unchanged. Biochemical liver
damage parameters were also within normal, with alkaline
phosphatase (ALP) levels being actually lower in treated groups
compared to control (p = 0.03), while ALT and AST showing no
significant differences (p = 0.44 and p= 0.17, respectively). Total
bilirubin (TBIL), albumin (ALB) and total protein (TP) content of
the blood was also unchanged. Together with the histological and
pathological analysis these results suggest that oral administration
of HPbCD-naringenin complex was not associated with any
adverse effects.
Discussion
Naringin is an abundant flavonone-glycoside known to cause
the bitter taste in grapefruit (citrus paradisi). The compound is
highly soluble and can be found in grapefruit juice at
concentrations of up to 0.5 g/L [26]. Following ingestion, naringin
is broken down by gut flora to its aglycone form, naringenin [27].
Naringenin has been the focus of multiple studies in recent years,
which began to elucidate its clinical potential as an antioxidant
with anti-carcinogenic, anti-inflammatory, and hypolipidemic
properties [2]. The flavonoid’s ability to reduce the secretion of
very-low density lipoprotein (VLDL) from hepatocytes has been
demonstrated in tissue culture, and attributed both to signaling
events, through the insulin-PI3K and MAPK pathways [6,28]; and
most recently, to the modulation of the PPARa, PPARc and
LXRa nuclear receptors [16,29]. Recently, our group demon-
strated that this inhibition of VLDL assembly blocked the
production of infectious HCV particles from infected hepatocytes
[15], while others point to naringenin’s hypolipidemic properties
in the treatment of diabetes [10]. As with other drugs, efficacy
would depend on the ability to deliver the molecule to patients in a
reproducible manner [21].
Cyclodextrins are a family of cyclical oligosaccharides, com-
posed of varying numbers of glucopyranoside rings that form a
three-dimensional toroid structure. The inner face of the toroid is
significantly less hydrophilic than the surrounding water, provid-
ing an energetic advantage to the insertion of hydrophobic
molecules into the cavity. b-cyclodextrins, specifically, are
composed of seven sugar rings, and have been shown to be non-
toxic to humans [21]. These cyclodextrins are widely used by the
food and pharmaceutical industries and a generally regarded as
safe [22]. The potential of b-cyclodextrins to enhance the solubility
and gut absorption of flavonoids was demonstrated by Uekama
and coworkers [19]. The group complexed the flavonoid-
glycoside, rutin with HPbCD and found a 10-fold increase in
solubility. Following the oral administration of the complex in
Table 1. Naringenin solubility in cyclodextrin solutions.
Naringenin (mM) Cyclodextrin (mM)
Fold increase
in solubility K
bCD 4.860.3 2061.0 132 6025
mbCD 19.060.9 5062.5 526 9975
HPbCD 15.861.4 5062.5 437 8203
doi:10.1371/journal.pone.0018033.t001
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beagle dogs the plasma concentration of rutin increased by nearly
3-fold. The hydrophobic nature of naringenin, and its structural
similarity to the quercetin unit in rutin, suggests that its delivery
could similarly be enhanced.
Naringenin suffers from low solubility in aqueous environments,
up to 36 mM in our hands, and is generally dissolved in organic
solvents [2]. In the presence of b-cyclodextrins, however, the
solubility of naringenin increased by several orders of magnitude,
up to 500-fold. Of the three cyclodextrin types tested, solubility
increased in the order mbCD.HPbCD.bCD. Despite the
superior ability of mbCD to solubilize naringenin, we chose to
conduct further experiments with HPbCD, which does not exert a
detergent-like effect on biological membranes causing irritation
and hemolysis [30] and is used in multiple drug formulations [31].
We next examined the ability of HPbCD to enhance the
delivery of naringenin across the intestinal mucosa. We used the
well-characterized Caco-2 transwell model of the human gut
epithelium [23]. In this experiment, a monolayer of Caco-2 gut
epithelial cells was grown on a transwell membrane, and the ability
of naringenin to cross this barrier is measured over time. When
complexed to HPbCD, naringenin reached a concentration
11-fold higher than in the absence of the excipient. Interestingly,
the rate of transport of naringenin across the membrane was not
different between the groups, set as 561 mM/min (p.0.10). The
integrity of the monolayer was verified both at the beginning and
end of the experiment suggesting that neither HPbCD nor
naringenin damaged the monolayer at the concentrations and
time-scales examined.
We next examined the ability of HPbCD to enhance the
bioavailability of naringenin in a rat model. Two groups of male
Sprague-Dawley rats were fed 20 mg/kg body weight naringenin.
One group was fed naringenin alone, while the other was fed a
HPbCD-naringenin complex. Our results indicate a substantial
improvement in the delivery of naringenin complexed with
HPbCD, with AUC0-10 of naringenin increasing 7.4-fold and
maximal concentration, Cmax, increasing 14.6-fold over narin-
genin alone. This increase in bioavailability represents an increase
in the absorption rate from Ka = 63.7 hr
21 to Ka
= 26.96104 hr21, a 4200-fold increase. Several effects could
explain this increased rate of transport, including enhancement
of dissolution kinetics, increase in solubility, decrease in degrada-
tion, change in the properties of the intestinal membrane, and
shuttling and enhancement of drug concentration at the intestinal
wall [31]. However, it is unlikely that complexation with HPbCD
changes the plasma pharmacokinetics of naringenin, as cyclodex-
trins are poorly transported across the intestinal wall [21]. The
calculated half-life for naringenin in plasma under both conditions
was 2.3 hrs, consistent with values previously reported in humans
[24,25] and rats [26]. The ratio of free naringenin to its
glucuronide form were also unchanged by the complex and
remained ,3% in both cases.
Using this information we devised a study in which naringenin
or the HPbCD-naringenin complex is given orally to rats 30 min
prior to a controlled meal rich in glucose and fat. This 30 min
period was judged sufficient to allow the flavonoid to induce
PPARa in liver and skeletal muscle through our recently described
induction of the PPAR co-activator PGC1a [16]. We show that
Figure 2. HPbCD enhances the bioavailability of naringenin. (a)
11 mM naringenin, either alone or in a complex with 45 mM HPbCD, was
added to the top apical chamber of a Caco-2 model of human intestinal
transport. In the presence of HPbCD, the concentration of naringenin was
increased in the bottom basal side from 40620 nM to 510670 nM,
representing an 11-fold enhancement of transport across the Caco-2
monolayer. (b) Phase image of Caco-2 monolayer grown for 21 days on
collagen-coated transwell membranes. Barrier resistance remained un-
changed during the course of the experiment. (c) Male Sprague-Dawley rats
were fed 20 mg/kg body weight naringenin either alone, or as a HPbCD-
naringenin complex. Blood samples were collected sequentially and
analyzed for naringenin content by LC-MS. HPbCD-naringenin complex
had higher oral bioavailability compared to naringenin alone. AUC0-10 of the
HPbCD-naringenin complex increased by 7.4-fold (p=0.005), and maximal
concentration, Cmax increased by 14.6-fold (p=0.002).
doi:10.1371/journal.pone.0018033.g002
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Figure 3. HPbCD-naringenin complex ameliorates the effects of a fat and glucose-rich meal. (a) Male Sprague-Dawley rats were fasted
overnight, and then fed 20 mg/kg body weight naringenin either alone or as a HPbCD-naringenin complex. 30 min later, the rats were administered a
meal composed of a suspension of 1 ml/kg olive oil and 1 g/kg glucose. Glucose clearance was measured as the rate of return to normal from
maximal concentration (about 65 min). (b) Plasma cholesterol, HDL, triglycerides, and ApoB100 (VLDL) were measured 3.5 hrs after the meal.
Cholesterol and HDL levels did not change. Triglyceride levels in rats fed the HPbCD-naringenin complex were elevated, but not significantly (p = 0.24,
n = 3). In contrast, plasma levels of ApoB100, the structural protein of VLDL, were significantly 42% lower (p = 0.05, n = 3) than rats given naringenin
alone. (c) mRNA abundance of PGC1a increased by 2306100% and 118660% in skeletal muscle and liver, respectively. Tissue samples were collected
3.5 hrs after the meal.
doi:10.1371/journal.pone.0018033.g003
Figure 4. Male Sprague-Dawley rats were fed 20 mg/kg body weight naringenin either alone, or as a HPbCD-naringenin complex.
Animals were sacrificed 10 hrs post-treatment and tissue samples were collected and preserved. Representative images of H&E histological
preparations from bowel, kidney, and liver are presented. Tissues were evaluated by a blinded pathologist and were judged to be normal with no
signs of inflammation or necrosis.
doi:10.1371/journal.pone.0018033.g004
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animals which received the complex showed significantly 64%
higher (p = 0.05, n= 3) rates of glucose clearance, compared to rats
given naringenin alone. Correspondingly, skeletal muscle expres-
sion of PGC1a measured by qRT-PCR significantly increased by
2306100% (p= 0.02, n = 3). In addition, 3.5 hrs after the meal,
plasma levels of ApoB100, the structural protein of VLDL were
significantly 42% lower (p= 0.05, n= 3) in rats given the complex
than rats given naringenin alone. Not surprisingly, the expression
of PGC1a in the liver was also increased by 118660%.
Interestingly, triglyceride levels in the complex-fed rats increased,
but not significantly (p = 0.24, n= 3). This response is similar to
that of fibrates that, like naringenin, act through PPARa, and is
thought to occur due to a flux of chylomicrons from the intestine
being ‘ignored’ by the liver.
Previous studies demonstrated the low bioavailability of
naringenin. Niopas and coworkers orally administered 135 mg
naringenin to six healthy volunteers. Plasma concentrations
peaked after 3.5 hrs, and bioavailability was estimated to be
5.8% [24]. Erlund and coworkers found similarly low bioavail-
ability when the source of naringenin was grapefruit juice. The
researchers also noted the high variability in bioavailability, which
was hypothesized to be the result of subject-to-subject variation in
gut microflora [25]. Importantly, plasma concentration of
naringenin attained in these trials is significantly lower than the
concentration required to attain a therapeutic effect, measured
both in vitro and in vivo. Huff and colleagues have demonstrated
that in HepG2 cells naringenin peak modulation of lipid
metabolism is attained around 200 mM [5]. A similar concentra-
tion of naringenin blocked the production of VLDL and HCV in
chronically infected Huh7.5.1 cells and primary human hepato-
cytes [15]. Our recent findings regarding the modulation of
PPARa and LXRa suggest a switch-like response to naringenin at
concentrations of around 150 mM [16] partly explaining why
animal experiment resort to either very high doses or several weeks
of treatment to demonstrate an effect.
Attaining plasma concentrations of 150–200 mM requires the
consumption of more than 5 g of naringenin, over 60 grapefruits
worth, at 5.8% bioavailability. In contrast, based on our work, less
than 400 mg of naringenin are required if the compound is
complexed with HPbCD. Considering the sugary taste of
cyclodextrin, it is no longer such a bitter pill to sallow.
Materials and Methods
Ethics Statement
All animals were treated in accordance with National Research
Council guidelines and approved by the Subcommittee on
Research Animal Care at the Massachusetts General Hospital
and the Hebrew University of Jerusalem. Experiments were
approved under IACUC protocol numbers 2009N000171 and
NS-10-12489-3 in the United States and Israel, respectively.
Materials
Naringenin, b-cyclodextrin (bCD), methyl b-cyclodextrin
(mbCD), and 2-hydroxypropyl-b-cyclodextrin (HPbCD) were
purchased from Sigma-Aldrich Chemicals (St. Louis, MO).
Caco-2 human epithelial colorectal adenocarcinoma cells were
purchased from the American Type Culture Collection (Rockville,
MD). Unless otherwise noted, all other chemicals were purchased
from Invitrogen Life Technologies (Carlsbad, CA).
Solubility curves of naringenin complexed with
cyclodextrin
Stock solutions of naringenin were prepared in ethanol. A
calibration curve was prepared by measuring the UV absorbance
of the naringenin stock solutions (0.1 to 0.6 mM) at 290 nm using
a ND-1000 spectrophotometer (NanoDrop Technologies, Rock-
land, DE). Standard deviations between triplicate measurements
were less than 5%.
Improvements in naringenin solubility when complexed with
cyclodextrin were determined and evaluated as follows; stock
solutions of bCD, mbCD, and HPbCD were prepared in distilled
water. None of the cyclodextrins absorbed at 290 nm for
concentrations from 0 to 50 mM (data not shown). Next, excess
amounts of naringenin powder were added to solutions containing
variable amounts of each cyclodextrin, vortexed, and incubated
with shaking at 37uC for 3-5 hrs. Naringenin-cyclodextrin solutions
were filtered through a 0.45 mm filter to remove the undissolved
naringenin, diluted by 20 or 50-fold, and absorbance was measured
at 290 nm. The complex stability constant K was calculated from
the linear portion of the solubility diagram assuming a 1:1 complex.
Caco-2 cell culture
Caco-2 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum,
1% nonessential amino acids, and 4 mM glutamine without
antibiotics. The cultures were grown in a humidified incubator at
37uC and 5% CO2. Cells between 30 and 53 passages were used.
Intestinal transport assay
For the transport studies, Caco-2 cells were seeded on Transwell
(0.4-mm pore size, 1-cm2 growth area; Corning Costar Co.) at a cell
density of 1x105 cells/filter. Cell growth and maintenance were
performed as previously described [32]. The cell monolayer was fed
fresh growth medium every 2 days and used on day 21 for the
transport experiments. HBSS supplement with 20 mM glucose and
10 mM HEPES (pH 7.35) was used as the transport medium. To
determine the amount of drug crossing the polarized Caco-2 cell
monolayer from the donor to the receiver (i.e., apical to basolateral),
the Caco-2 cells were rinsed twice with pre-warmed transport
Table 2. Comprehensive Metabolic Panel of naringenin-
treated male Sprague-Dawley rats compared with untreated
controls.
HPbCD-Naringenin Naringenin Control
Na+ 139.061.0 138.061.0 134.362.5
K+ 5.960.6 5.360.3 4.460.7
Cl- 102.061.0 102.062.0 89.763.9
Glu 168.0614.4 157.066.1 181.2626.5
Ca2+ 9.360.7 9.760.2 10.260.5
BUN 16.763.1 19.365.1 14.063.6
Cre 0.260.0 0.360.0 0.460.1
ALP 147.3684.6 135.3637.5 311.7664.6
ALT 56.7611.1 61.3620.3 59.8630.4
AST 307.36107.8 248.3645.5 205.76124.0
TBIL 0.360.0 0.360.1 0.460.0
ALB 1.660.2 1.660.3 2.160.1
TP 5.660.5 5.660.5 6.260.3
Glu, Glucose; BUN, blood urea nitrogen; Cre, Creatinine; ALP, alkaline
phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; TBIL,
total bilirubin; ALB, albumin; TP, total protein.
doi:10.1371/journal.pone.0018033.t002
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medium and incubated by pre-warmed transport medium 0.2 ml for
apical chamber and 0.5 ml for basolateral chamber at 37uC for
30 min. A 60 mg/ml (1% DMSO in HBSS) stock solution of test
compounds, either naringenin or HPbCD-naringenin, was added
and samples from both apical and basolateral were taken (30 ml) at
different time points: 30, 60, 120, 150 180, 240, and 300 min. The
integrity of the culture was confirmed by transepithelial electrical
resistance (TEER) and by detecting fluorescently labeled cells using
60 mM of Lucifer Yellow as a standard. The concentrations of
naringenin or HPbCD-naringenin were determined as described
and plotted as a concentration on the basolateral side vs. time.
Concentrations were corrected by the dilution factor as fresh buffer
was added after sampling.
Animal experiments
Adult male Sprague-Dawley rats were purchased from Charles
Rivers Laboratories (Wilmington, MA). Upon arrival, each rat was
isolated for 3–5 days towards adaptation to the new environment.
Animals were housed under 12h cycle of day/night with free
access to drinking water and fed ad libitum unless otherwise noted.
To measure the pharmacokinetic profile of naringenin, rats
weighing between 280 and 300 g were anaesthetized using
intraperitoneal injections of ketamine and xylazine at 110 and
0.4 mg/kg, respectively. The left carotid artery was cannulated
using a 0.76-mm diameter660-cm length heparanized catherter.
The catheter was tunneled subcutaneously from the opening made
in the anterior face of the neck to the dorsal site of the neck and
permanently anchored in the skin. The catheter was secured by
the use of a rat jacket. Animals were placed in their cages during
the term of the study. Animals were orally administered with
20 mg/kg body weight of naringenin in either water or complexed
with 320 mg/kg body weight HPbCD using a rat oral gavage (18G
61 1/20 plastic feeding tube from Instech Laboratories, Inc, PA,
USA). Blood samples (0.5 ml) were collected at 0, 15, 30, 60, 120,
240, 360, 510, and 600 min from the carotid artery using the
previously placed catheter. In two additional experiments, animals
were placed in metabolic cages and urine was collected and pooled
for the duration of the experiment.
To measure metabolic changes, rats weighing between 270 to
290 g were fasted for 16 hrs, but allowed free access to water.
Animals were orally administered with 20 mg/kg body weight of
naringenin in either water or complexed with 320 mg/kg body
weight HPbCD using a rat oral gavage. Precisely 30 min after the
oral administration of naringenin, the rats were administered
1 ml/kg of olive oil suspended in PBS with 1 g/kg of glucose using
rat oral gavage. Glucose was measured using a single tail snip and
repeated scratching on an Accu-Chek Sensor (Roche, Branford,
CT) prior to the experiment and at 0, 15, 30, 60, 90, and 120 min
from the meal. Rats were anaesthetized 200 min following the
meal using intraperitoneal injection of ketamine and xylazine
followed by terminal blood draw and tissue collection.
LC-MS detection of naringenin
LC-MS analysis was performed on an Agilent Technologies
series 1100 LC-MSD system (Santa Clara, CA), which included an
Agilent 1100 quaternary pump, autosampler, column oven, on-
line vacuum degassor, and single quadrupole mass spectrometer
equipped with electrospray ion source (ESI).
Mass spectrometry conditions: Electrospray ionization (ESI),
positive, selected ion monitoring scan (SIM); SIM: naringenin m/z
273.1. LC conditions: Eclipse XDB-C18 column (4.66150mm,
5.0 mm). The mobile phase was composed of methanol-water with
0.1% formic acid (65:35,v/v). The isocratic flow rate was set at
0.8 ml/min and injection volume was only 10 ml.
To each 100 ml of rat serum sample, 100 ml of 0.1N sodium
acetate (pH=5.0) and 100 ml of b-glucuronidase enzyme (5000
units/ml, type HP-2 from Helix Pomatia) were added and
vortexed for 5 seconds. This process hydrolyzes the conjugated
form of naringenin to determine total naringenin in plasma. After
addition of 20 ml IS buffer solution (5 mg/ml), the sample was then
incubated at 37uC water bath for 18 h.
The sample was extracted with 0.8 ml of ethyl acetate after 18 h
incubation, and centrifuged at 13000 rpm for 10 min. The
supernatant was collected and evaporated to dryness under
nitrogen at room temperature. The residue was reconstituted
with 100 ml of mobile phase and filtered through a micro nylon n
filter (0.45 mm). 10 ml of the filtrate was forwarded to LC-MS
analysis. A calibration curve was established and QC samples
conducted (data not shown). Data acquisition was performed using
ChemStation software (Agilent). Linear regression (weighted by
1/x) between serum concentration and peak area ratio of
naringenin to IS was constructed using SPSS11.0 statistical
software. The concentrations of naringenin in samples were
calculated by interpolation of the linear equation.
Quantitative Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
Liver and skeletal muscle tissues were ground in liquid nitrogen,
homogenized and RNA was purified using BioRad Aurum Total
RNA Fatty and Fibrous Tissue Kit (Hercules, CA). Total RNA was
quantified on NanoDrop Technologies, ND-1000 spectrophotom-
eter (Wilmington, DE) and mRNA transcript abundance was
measured on a BioRad CFX96 real-time PCR Detection System
using Bio-Rad SsoFastTM EvaGreenH supermix (Hercules, CA),
according to the manufacturers’ instructions. PGC1a (PPARGC1a)
primers used were, forward GACCCCAGAGTCACCAAATGA
and reverse GGCCTGCAGTTCCAGAGAGT, while b-Actin
(ACTB) used were, forward AGCCATGTACGTAGCCATCCA
and reverse TCTCCGGAGTCCATCACAATG (Integrated DNA
Technologies, Coralville, IA). Expression was normalized to b-Actin
using DDCt.
Metabolism
Liver metabolic and lipid plasma levels were analyzed using
Piccolo Blood Analyzer (Abaxis, Union City, CA) and confirmed
by A.M.L veterinary department (Herziliya, Israel). Levels of rat
apolipoprotein B100 (APOB100) were measured using ELISA
(Uscn Life Sciences, Wuhan, China).
Liver Histology
Histological sections of each organ were taken 10 hours after
treatment. Formalin-fixed, paraffin-embedded liver, intestine, and
kidney samples were sectioned at 4 mm and stained with
hematoxylin & eosin (H&E). Histological characterization was
performed by a blinded observer using standard assessment of
damage.
Statistics
Data are expressed as the mean 6 standard deviation.
Statistical significance was determined by a one-tailed Student’s
t-test. A P-value of 0.05 was used for statistical significance.
Supporting Information
Figure S1 Glucose plasma concentrations over time in rats
administered a high fat (1 ml/kg) high glucose (1 g/kg) meal at
time zero. 30 minutes prior to the meal, the rats were administered
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either naringenin alone or HPbCD-naringenin complex. Curves
represent average 6 standard deviation of 3 rats in each group.
(PDF)
Author Contributions
Conceived and designed the experiments: YN CWL-P. Performed the
experiments: MS MC AS-G HY HW OB-R YN. Analyzed the data: MS
MC HW YN. Contributed reagents/materials/analysis tools: HW OB-R.
Wrote the paper: YN JG. Contributed research space: MLY.
References
1. Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry,
bioavailability and effects on health. Natural product reports 26: 1001–1043.
2. Wilcox LJ, Borradaile NM, Huff MW (1999) Antiatherogenic Properties of
Naringenin, a Citrus Flavonoid. Cardiovascular Drug Reviews 17: 168–178.
3. Jung UJ, Kim HJ, Lee JS, Lee MK, Kim HO, et al. (2003) Naringin
supplementation lowers plasma lipids and enhances erythrocyte antioxidant
enzyme activities in hypercholesterolemic subjects. Clinical Nutrition 22:
561–568.
4. Renugadevi J, Prabu SM (2009) Naringenin protects against cadmium-induced
oxidative renal dysfunction in rats. Toxicology 256: 128–134.
5. Wilcox LJ, Borradaile NM, Dreu LEd, Huff MW (2001) Secretion of hepatocyte
apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced
activity and expression of ACAT2 and MTP. Journal of Lipid Research 42:
725–734.
6. Allister EM, Borradaile NM, Edwards JY, Huff MW (2005) Inhibition of
microsomal triglyceride transfer protein expression and apolipoprotein B100
secretion by the citrus flavonoid naringenin and by insulin involves activation of
the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 54:
1676–1683.
7. Kidambi S, Yarmush RS, Novik E, Chao P, Yarmush ML, et al. (2009) Oxygen-
mediated enhancement of primary hepatocyte metabolism, functional polariza-
tion, gene expression, and drug clearance. Proc Natl Acad Sci U S A 106:
15714–15719.
8. Huong DT, Takahashi Y, Ide T (2006) Activity and mRNA levels of enzymes
involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. Nutrition
22: 546–552.
9. Fuhr U, Kummert AL (1995) The fate of naringin in humans: a key to grapefruit
juice-drug interactions? Clin Pharmacol Ther 58: 365–373.
10. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, et al. (2009)
Naringenin prevents dyslipidemia, apoB overproduction and hyperinsulinemia
in LDL-receptor null mice with diet-induced insulin resistance. Diabetes 58:
2198–2210.
11. Kurowska E, Borradaile N, Spence JD, Carroll KK (2000) Hypocholesterolemic
effects of dietary citrus juices in rabbits. Nutr Res 20: 121–129.
12. Jeon SM, Kim HK, Kim HJ, Do GM, Jeong TS, et al. (2007) Hypocholes-
terolemic and antioxidative effects of naringenin and its two metabolites in high-
cholesterol fed rats. Transl Res 149: 15–21.
13. Allister EM, Mulvihill EE, Barrett PHR, Edwards JY, Carter LP, et al. (2008)
Insulin-like effects of naringenin on inhibition of apolipoprotein B secretion from
HepG2 cells. The Journal of Lipid Research 49: 2218–2229.
14. Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, et al. (2008)
Inhibition of apoB secretion from HepG2 cells by insulin is amplified by
naringenin, independent of the insulin receptor. J Lipid Res 49: 2218–2229.
15. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, et al. (2008)
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the
grapefruit flavonoid naringenin. Hepatology 47: 1437–1445.
16. Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, et al. (2010)
Transcriptional Regulation of Human and Rat Hepatic Lipid Metabolism by the
Grapefruit Flavonoid Naringenin: Role of PPARa, PPARc and LXRa. PLoS
One 5: pii: e12399.
17. Rajewski, Stella (1996) Pharmaceutical applications of cyclodextrins. 2. In vivo
drug delivery. Journal of pharmaceutical sciences 85: 1142–1169.
18. Stella, Rajewski (1997) Cyclodextrins: their future in drug formulation and
delivery. Pharm Res 14: 556–567.
19. Miyake K, Arima H, Hirayama F, Yamamoto M, Horikawa T, et al. (2000)
Improvement of Solubility and Oral Bioavailability of Rutin by Complexation
with 2-Hydroxypropyl-b-cyclodextrin. Pharmaceutical Development and Tech-
nology 5: 399–407.
20. Tommasini S, Raneri D, Ficarra R, Calabro` ML, Stancanelli R, et al. (2004)
Improvement in solubility and dissolution rate of flavonoids by complexation
with beta-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis 35:
379–387.
21. Stella VJ, He Q (2008) Cyclodextrins. Toxicol Pathol 36: 30–42.
22. Challa R, Ahuja A, Ali J, Khar RK (2005) Cyclodextrins in drug delivery: an
updated review. AAPS PharmSciTech 6: E329–357.
23. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, et al. (2005) The
Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-
related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21:
1–26.
24. Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I (2007) Pharmacokinetics of
the citrus flavanone aglycones hesperetin and naringenin after single oral
administration in human subjects. European Journal of Clinical Nutrition 61:
472–477.
25. Erlund I, Meririnne E, Alfthan G, Aro A (2001) Plasma kinetics and urinary
excretion of the flavanones naringenin and hesperetin in humans after ingestion
of orange juice and grapefruit juice. J Nutr 131: 235–241.
26. Ya´n˜ez JA, Remsberg CM, Miranda ND, Vega-Villa KR, Andrews PK, et al.
(2008) Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and
eriodictyol in rats and their content in fruit juices. Biopharmaceutics & drug
disposition 29: 63–82.
27. Choudhury R, Chowrimootoo G, Srai K, Debnam E, Rice-Evans CA (1999)
Interactions of the flavonoid naringenin in the gastrointestinal tract and the
influence of glycosylation. Biochem Biophys Res Commun 265: 410–415.
28. Borradaile NM, Dreu LEd, Huff MW (2003) Inhibition of Net HepG2 Cell
Apolipoprotein B Secretion by the Citrus Flavonoid Naringenin Involves
Activation of Phosphatidylinositol 3-Kinase, Independent of Insulin Receptor
Substrate-1 Phosphorylation. Diabetes 52: 2554–2561.
29. Liu L, Shan S, Zhang K, Ning Z-Q, Lu X-P, et al. (2008) Naringenin and
Hesperetin, Two Flavonoids Derived from Citrus aurantium Up-regulate
Transcription of Adiponectin. Phytotherapy Research 22: 1400–1403.
30. Ilangumaran S, Hoessli DC (1998) Effects of cholesterol depletion by
cyclodextrin on the sphingolipid microdomains of the plasma membrane.
Biochem J 335(Pt 2): 433–440.
31. Carrier RL, Miller LA, Ahmed I (2007) The utility of cyclodextrins for
enhancing oral bioavailability. J Control Release 123: 78–99.
32. Gao J, Hugger ED, Beck-Westermeyer MS, Borchardt RT (2000) Estimating
Intestinal Mucosal Permeation of Compounds Using Caco-2 Cell Monolayers.
In: Enna SJ, Williams M, eds. Current Protocols in Pharmacology (2000) John
Wiley & Sons. pp 7.2.1–7.2.23.
Enhanced Naringenin Bioavailability
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18033
